Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Shares Cross Below 200 Day Moving Average – Should You Sell?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $31.10 and traded as low as $28.21. Lakefront Biotherapeutics American Depositary Shares shares last traded at $28.37, with a volume of 125,293 shares.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, May 26th. Royal Bank Of Canada lifted their price objective on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 24th. Wall Street Zen cut Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. UBS Group reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, February 24th. Finally, Zacks Research raised Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $36.50.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

The company has a 50-day simple moving average of $28.17 and a two-hundred day simple moving average of $31.10. The firm has a market capitalization of $1.87 billion, a P/E ratio of -20.12 and a beta of 0.26.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its quarterly earnings results on Sunday, February 15th. The biotechnology company reported $13.92 EPS for the quarter. The company had revenue of $1.06 billion during the quarter. As a group, research analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -6.32 earnings per share for the current fiscal year.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

Hedge funds have recently made changes to their positions in the stock. State of Wyoming bought a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the 2nd quarter worth approximately $28,000. Van ECK Associates Corp boosted its position in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% in the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 750 shares in the last quarter. Arax Advisory Partners boosted its position in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% in the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 1,778 shares in the last quarter. Quadrant Capital Group LLC bought a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter worth approximately $134,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter worth approximately $211,000. 32.46% of the stock is owned by institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.